



By constructing a specialised factory in Udaipur, Rajasthan, Mankind Pharma is preparing to compete with Abbott India's top-selling synthetic hormone brand Duphaston (dydrogesterone), which is used to treat infertility and prevent miscarriage.

Mankind is investing about ₹250-₹300 crore on the Udaipur unit that is expected to begin operations by September-October this year.

Mankind Pharma has a strong portfolio of products ranging from pharma to over-the-counter and FMCG brands with an employee base of more than 12,000.

### **Site Moved. Visit our New Website**

We have moved this news site from this URL

to <https://www.newprojectstracker.com/capex-news> .

Visit this site for regular updates

Buy Latest Research Reports